278

Index

measures, 234

modules, 232

mood disorders, 174, 185

motor imagery (MI), 177, 185

MS-based proteomics, 263

multiple sclerosis (MS), 17, 56,

207, 210

clinical manifestations, 17

clinical trials in MS, 57

demyelination, 17

diagnosis, 17

HSCs in MS, 57

microarray studies, 207

MSCs in MS, 56

RNA-seq studies, 210

treatment, 17

N

natural language processing

(NLP), 185

network alignment, 237

brain, 238

graph matching, 238

quality, 238

network models, 230

network motifs, 235

network visualization

Cytoscape, 204

neuroblasts, 46

neurodegeneration, 8, 42

neurodegenerative diseases, 7, 42,

185, 250, 263

Alzheimer’s disease (AD), 8,

174, 185

amyotrophic lateral sclerosis

(ALS), 15

experimental studies, 48

Huntington’s disease (HD),

13

mild cognitive impairment

(MCI), 185

multiple sclerosis (MS), 17

Parkinson’s disease (PD), 9,

174, 185

neurogenesis, 46

neuroimaging, 174, 175, 185

neuroimaging informatics, 212

neuroimaging techniques

EEG, 174–182, 185, 187, 188

electrocorticography (ECoG),

177

electroencephalogaphy

(sEEG), 177

fMRI, 174, 175, 185

iEEG, 175, 177

magnetoencephalography

(MEG), 185

near-infrared spectroscopy

(NIRS), 185

positron emission

tomography (PET), 185

neuropsychiatric diseases, 174,

185, 188

neuropsychiatric disorders, 20

attention deficit hyperactivity

disorder (ADHD), 22

autism spectrum disorder

(ASD), 24

bipolar disorder (BD), 22,

185

depression, 185

major depressive disorders

(MDD), 23, 185

schizophrenia, 21, 174, 185

neuropsychology, 20

NGS

advantages, 201

disdvantages, 202

Illumina, 201

Ion Torrent, 201

Pacific Biosciences, 201

quality control, 201

Roche 454, 201

SOLID, 201

NIRS, 185

P

P300, 179

Parkinson’s disease (PD), 9, 54,

174, 185, 206, 210, 260